A new trading day began on Friday, with Calidi Biotherapeutics Inc (AMEX: CLDI) stock price down -6.21% from the previous day of trading, before settling in for the closing price of $1.45. CLDI’s price has ranged from $0.73 to $18.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -50.00%. Meanwhile, its annual earnings per share averaged 78.64%. With a float of $16.76 million, this company’s outstanding shares have now reached $93.11 million.
Let’s determine the extent of company efficiency that accounts for 41 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Calidi Biotherapeutics Inc (CLDI) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Calidi Biotherapeutics Inc is 11.10%, while institutional ownership is 1.63%. The most recent insider transaction that took place on Dec 17 ’24, was worth 16,200. In this transaction CEO and Chairman of the Board of this company sold 10,000 shares at a rate of $1.62, taking the stock ownership to the 66,712 shares.
Calidi Biotherapeutics Inc (CLDI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 78.64% per share during the next fiscal year.
Calidi Biotherapeutics Inc (AMEX: CLDI) Trading Performance Indicators
Here are Calidi Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.81, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Calidi Biotherapeutics Inc (CLDI)
Looking closely at Calidi Biotherapeutics Inc (AMEX: CLDI), its last 5-days average volume was 1.12 million, which is a jump from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 8.22%. Additionally, its Average True Range was 0.25.
During the past 100 days, Calidi Biotherapeutics Inc’s (CLDI) raw stochastic average was set at 19.94%, which indicates a significant increase from 10.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.57% in the past 14 days, which was lower than the 160.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6698, while its 200-day Moving Average is $2.2187. However, in the short run, Calidi Biotherapeutics Inc’s stock first resistance to watch stands at $1.4767. Second resistance stands at $1.5933. The third major resistance level sits at $1.6967. If the price goes on to break the first support level at $1.2567, it is likely to go to the next support level at $1.1533. Should the price break the second support level, the third support level stands at $1.0367.
Calidi Biotherapeutics Inc (AMEX: CLDI) Key Stats
With a market capitalization of 24.04 million, the company has a total of 13,078K Shares Outstanding. Currently, annual sales are 0 K while annual income is -29,220 K. The company’s previous quarter sales were 0 K while its latest quarter income was -5,070 K.
